iShares U.S. Pharmaceuticals ETF (IHE)

NYSE · US Equities - Industry Sector · USA

Are the companies inside IHE undervalued?

The companies inside IHE trade 13% above what we estimate they are worth. We could give a verdict on 87% of the fund's weight: 59 holdings as reported to the SEC at 30 Jun 2026.

Where the money is: 15% in companies in the buy zone, 1% about fairly valued, 71% overvalued, 13% without a verdict.

What does IHE hold?

The ten largest holdings, with our verdict on each:

How much does the IHE fee cost?

Its expense ratio is 0.37% a year: on $10,000 held flat that is $370 over 10 years and $740 over 20.

Browse

Other US Equities - Industry Sector ETFs